Converge Bio
PrivateLast Round
Grant
Jun 2, 2026
Est. Valuation
$90M
Total Funding Raised
$33M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Converge Bio operates in Healthcare & Life Sciences and is based in Tel Aviv. Its latest recorded funding round was a Grant round in June 2026.
Converge Bio is a biotechnology company that provides a generative AI platform using large language models trained on biological and chemical data to accelerate drug discovery and development for pharmaceutical companies.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, ML Platforms
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Converge Bio Comparables
Compare Converge Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cradle | 84% | |
| Bioptimus | 80% | |
| Aureka Biotechnologies | 79% |
For institutional investors. Book with your work email.
Converge Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 2, 2026 | ||||
| Series A | Jan 13, 2026 | ||||
| Early Stage VC | Sep 24, 2025 | ||||
| Seed | Nov 20, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Converge Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Saras Capital | Series A |
| Vintage Investment Partners | Series A |
| TLV Partners | Series A, Seed |
| Bill & Melinda Gates Foundation | Grant |
| Bessemer Venture Partners | Series A, Early Stage VC |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 2, 2026
$3M grant received from Bill & Melinda Gates Foundation.
- Jan 13, 2026
$25M round completed.
For institutional investors. Book with your work email.
Converge Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Converge Bio's valuation, stock price, and market status.
Is Converge Bio a public or private company?
Converge Bio is a private company.
What is the current stock price of Converge Bio?
Converge Bio is a private company, so its shares have no public market price. Caplight tracks Converge Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Converge Bio worth (valuation)?
Converge Bio's valuation is estimated at $90.0M based on funding round data.
Can I buy Converge Bio stock?
Converge Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Converge Bio's last funding round?
Converge Bio's most recent funding round was Grant on June 2, 2026.
Who are the main investors in Converge Bio?
Key investors in Converge Bio include TLV Partners, Bill & Melinda Gates Foundation, Bessemer Venture Partners.
Will Converge Bio IPO soon?
No public IPO plans have been announced for Converge Bio.
How can I track Converge Bio secondary market activity?
Caplight tracks bids, offers, and trades in Converge Bio's shares on secondary markets.